Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  Celyad    CYAD   BE0974260896

CELYAD

(CYAD)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
02/15/2019 02/18/2019 02/19/2019 02/20/2019 02/21/2019 Date
18.3(c) 18.15(c) 17.9(c) 17.9(c) 17.94 Last
14 754 18 617 11 439 12 719 9 871 Volume
+2.23% -0.82% -1.38% 0.00% +0.22% Change
More quotes
Financials (EUR)
Sales 2018 4,48 M
EBIT 2018 -35,5 M
Net income 2018 -34,6 M
Finance 2018 29,0 M
Yield 2018 -
Sales 2019 9,88 M
EBIT 2019 -29,5 M
Net income 2019 -32,1 M
Finance 2019 0,57 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 41,2x
EV / Sales2019 21,6x
Capitalization 214 M
More Financials
Company
Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell-based therapies. Celyad utilizes its expertise in cell engineering to target cancer. Celyad's CAR-T cell platform has the potential to treat a broad range of solid and hematologic tumors. Its... 
Sector
Biotechnology & Medical Research
Calendar
02/28 | 01:30pmPresentation
More about the company
Surperformance© ratings of Celyad
Trading Rating : Investor Rating :
More Ratings
Latest news on CELYAD
01/31BONE THERAPEUTICS : holds successful event to highlight strength of cell and gen..
AQ
01/07CELYAD : Letter to Shareholders - January 2019
PU
01/07CELYAD : Presents Update on CYAD-01 Hematological Malignancies Clinical Program ..
AQ
2018CELYAD : Doses First mCRC Patient in the Phase 1 alloSHRINK Trial Evaluating Non..
AQ
2018CELYAD : - Celyad : Announces Third Quarter 2018 Business Update
AQ
2018CELYAD SA : quaterly earnings release
2018CELYAD : - Celyad : to Present New CYAD-01 Data from THINK Study in Relapsed/Ref..
AQ
2018CELYAD : Announces Exclusive Agreement for Horizon Discoverys shRNA Platform to ..
AQ
2018CELYAD : - Celyad : Announces Exclusive Agreement for Horizon Discovery's shRNA ..
AQ
2018CELYAD : appoints Carri Duncan as Vice-President Corporate Development & Communi..
AQ
More news
Analyst Recommendations on CELYAD
More recommendations
Sector news : Biotechnology & Medical Research - NEC
02/20GLOBAL MARKETS LIVE : Nissan, Lockheed Martin, UBS, Sainsbury...
02/12MARKET SNAPSHOT: Stocks Close At 2019 High On Tentative Deal To Avert Governm..
DJ
02/11Regeneron, Sanofi to Offer Praluent at Reduced U.S. List Price
DJ
02/11Sanofi and Regeneron cut list price of cholesterol drug by 60 percent
RE
02/06REGENERON PHARMACEUTICALS : 4Q Profit Rises
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart CELYAD
Duration : Period :
Celyad Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELYAD
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 34,8 €
Spread / Average Target 94%
EPS Revisions
Managers
NameTitle
Christian Homsy Chief Executive Officer & Executive Director
Michel E. Lussier Chairman
Jean-Pierre Latere Chief Operating Officer
Filippo Joseph Petti Chief Financial Officer
Frederic Lehmann VP-Clinical Development & Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
CELYAD7.90%242
IQVIA HOLDINGS INC22.11%28 245
CELLTRION, INC.--.--%24 286
LONZA GROUP13.78%21 553
INCYTE CORPORATION32.33%17 924
SEATTLE GENETICS, INC.26.16%11 201